Self-Assessment Tuberculin Skin Test (ISAT)
Innovation of Self-Assessment Tuberculin Skin Test for Latent TB Screening in HIV Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Bangkok, Thailand, 10330
- HIV-NAT, Thai Red Cross AIDS Research Centre
-
Bangkok, Thailand, 10600
- Taksin Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Documented HIV-1 infection
- Aged ≥18 years old
- No sign and symptom of active TB
Exclusion Criteria:
1. Refuse to read TST by themselves
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
HIV-infected participants who receive TST test
0.1 ml of tuberculin purified protein derivative will be intra-dermally inoculated on the forearm of the HIV-infected participants.
They will learn how to interpret the results of the TST test.
When they return to the clinic, the nurse will also interpret the results of the TST test.
The results from the participants will be compared to the nurses' interpretation.
We will assess the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the innovative method.
|
The participants do not receive any intervention for this study
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
self-assessment versus nurse reading
Time Frame: 6 months
|
this study will assess the sensitivity of this new innovative method for reading TST
|
6 months
|
|
self-assessment versus nurse reading
Time Frame: 6 months
|
this study will assess the specificity of this new innovative method for reading TST
|
6 months
|
|
self-assessment versus nurse reading
Time Frame: 6 months
|
this study will assess the positive predictive value (PPV) of this new innovative method for reading TST
|
6 months
|
|
self-assessment versus nurse reading
Time Frame: 6 months
|
this study will assess the negative predictive value (NPV) of this new innovative method for reading TST
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
In house questionnaire to assess the patients' satisfaction of reading TST by themselves
Time Frame: 6 months
|
Evaluation of patients' satisfaction in self- assessment TST by using questionnaires
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- HIV-NAT 260
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.